15 Dec 2022

2022 in review: ENPICOM’s highlights

As 2022 is coming to an end, we can’t help but look back with pride at what we have accomplished thus far, while eagerly looking forward to our future achievements. Let’s dive into some of the year’s biggest milestones for ENPICOM.


Scaling operations with Series B funding and Amazon Web Services

We kick-started 2022 with the closing of a capital investment round led by BOP Capital. This additional growth capital has allowed the company to support the rapidly expanding customer base for our unique SaaS proposition, the IGX Platform, in order to boost the candidate selection processes related to therapeutic antibody discovery.

To further support and improve speed and scalability of antibody discovery, we selected Amazon Web Services (AWS) as our new cloud provider in March 2022. The choice of AWS has been crucial in ENPICOM’s strive to innovate faster, facilitate research and streamline the client experience.


Introducing a new App for seamless analysis of antibody display data

At the Antibody Engineering & Therapeutics conference in June, we unveiled our brand new IGX Platform App for enrichment analysis: IGX-Track. With this addition, we have expanded the capabilities of the IGX Platform to unlock seamless analysis of antibody panning data. This major development is aimed at allowing researchers to analyze antibody display data in an intuitive and visual way, easily perform multi-dataset comparisons, and identify a diverse set of enriched candidates with the best characteristics. If you missed it, watch our free on-demand webinar to see IGX-Track in action.



Growing and helping others grow

In May, Genovac, a leading contract research and manufacturing organization (CRO/CMO) that discovers, develops, and manufactures antibodies, adopted ENPICOM’s IGX Platform for their antibody discovery workflows. Ever since, Genovac has relied on the IGX Platform’s advanced data management and computational analysis functionalities to enable client success and easier discovery of diverse, quality antibodies in the shortest amount of time. This is just one example of many new clients that we added to our customer base, but were not able to disclose this year.

Our growth is reflected in the expansion of our team as well: from 31 employees at the start of the year to 49 employees now. Over the summer, we have also expanded our management team with the addition of Paul van der Velde as Chief Operating Officer and Daan Prince for parttime CFO support, both experienced professionals that have helped to strengthen our operational processes and support ENPICOM’s financial growth. As we are still growing, we are constantly looking for enthusiastic people that want to build the future with us, so be sure to check our current vacancies.

As part of our continuous drive for improvement, ENPICOM successfully completed the ISO 27001:2013 certification project in October. By having a world-class security system in place, we can continue to pursue excellence in our business operations, technology, and customer experience.

Expanding and sharing our knowledge

This has been a prolific conference year that has seen our team attend many of the world’s leading life science and antibody events. Starting with the 21st annual PepTalk in January and finishing with the Antibody Engineering & Therapeutics US in December, we have shared our domain expertise with a numerous and diverse audience. Be sure to check our Events and Resources pages to learn more about all the conferences we attended and to watch our free recordings and webinars.



Moreover, we continued building our collaboration with prominent experts in the field, such as the Inno4Vac consortium, which we met again in October to further develop our partnership and strengthen our teamwork on vaccine development.

Our experts have also been busy creating blog articles to promote a deeper understanding of a variety of topics, such as:


Looking to the future

In September this year, we reached an important milestone: our 5-year anniversary. In five years the ENPICOM team has grown to over 50 people, built a leading-edge software solution to contribute to the battle against deadly diseases like cancer and serves clients around the globe.

The journey ahead is one we look very much forward to. 2022 has come to a close, but we are not winding down. As always, we are committed to continue working towards our goals with passion and purpose and drive immunotherapy discovery and development and bring better and more affordable therapies to patients in need faster.

We are thankful to our team, customers and partners for a successful and memorable 2022, and wish that 2023 will be at least as remarkable.